Back to Journals » OncoTargets and Therapy » Volume 9

β-Elemene treatment of glioblastoma: a single-center retrospective study

Authors Ma C, Zhou W, Yan Z, Qu M, Bu X

Received 27 August 2016

Accepted for publication 1 October 2016

Published 12 December 2016 Volume 2016:9 Pages 7521—7526

DOI https://doi.org/10.2147/OTT.S120854

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly


Chunxiao Ma, Wei Zhou, Zhaoyue Yan, Mingqi Qu, Xingyao Bu

Department of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China

Abstract:
Glioblastoma (GBM) is the most common primary malignancy in the central nervous system. In this study, we investigated the therapeutic effects of β-elemene (ELE) treatment in patients with newly diagnosed GBM who received concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide. Our results indicated that compared with control, patients who received ELE showed significantly longer median progression-free survival (PFS) (8 months vs 11 months; P<0.001) and overall survival (OS) (18 months vs 21 months; P<0.001). Despite the O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, ELE treatment could significantly prolong the PFS (P=0.038) and OS (P=0.016). In multivariate analysis, ELE was a significant prognostic factor for PFS (hazard ratio [HR], 0.34; 95% confidence interval [95% CI]: 0.15–0.62; P=0.011) and OS (HR, 0.31; 95% CI: 0.14–0.69; P=0.006). Furthermore, ELE could significantly reduce the hematologic toxicities induced by chemoradiotherapy. In conclusion, ELE might provide a survival benefit in patients with GBM. Further study for verification might be needed.

Keywords: glioblastoma, chemoradiotherapy, temozolomide, β-elemene
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]